The US Patent and Trademark Office published on Oct. 9 three patent applications claiming technology related to RNA interference.

The first application, entitled Method and reagent for the treatment of asthma and allergic conditions, claims nucleic acid molecules, including antisense, enzymatic nucleic acid molecules, and RNA interference molecules — such as hammerhead ribozymes, DNAzymes, allozymes, siRNA, decoys, and antisense —”which modulate the expression of prostaglandin D2 (PTGDS), prostaglandin D2 receptor (PTGDR), and adenosine receptor genes.”